IMARC Group, a leading market research company, has recently released a report titled "Drug-Eluting Stents Market Report by Coating (Polymer Based Coating, Polymer Free Coating), Drug (Sirolimus, Paclitaxel, Zotarolimus, Everolimus, Biolimus, and Others), Stent Platform (Stainless-steel, Cobalt-Chromium, Platinum-Chromium, Nitinol, and Others), Generation (1st Generation, 2nd Generation, 3rd Generation, 4th Generation), Application (Coronary Artery Disease, Peripheral Artery Disease), End User (Hospitals, Ambulatory Surgical Centers, and Others), and Region 2024-2032". The study provides a detailed analysis of the industry, including the global drug-eluting stents market trends, size, share and growth forecast. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
The global drug-eluting stents market size reached US$ 8.3 Billion in 2023. Looking forward, the market is expected to reach US$ 13.7 Billion by 2032, exhibiting a growth rate (CAGR) of 5.51% during 2024-2032.
Request to Get the Sample Report: https://www.imarcgroup.com/drug-eluting-stents-market/requestsample
Factors Affecting the Growth of the Drug-Eluting Stents Industry:
- Rapid Technological Advancements and Innovations:
The continuous research and development (R&D), leading to the creation of newer, more effective stents that offer enhanced safety and efficacy, is boosting the market growth. Along with this, the development of bioresorbable stents, which are designed to dissolve after the artery has healed, thereby reducing long-term complications is fostering the market growth. Additionally, the rising improvements in polymer coatings and drug formulations that contribute to better patient outcomes by minimizing restenosis and reducing the risk of stent thrombosis are enhancing the market growth. Besides this, the growing investment in next-generation stents that incorporate advanced materials and drug-eluting mechanisms to ensure precise drug delivery and optimal therapeutic effects is boosting the market growth.
- Increasing Prevalence of Cardiovascular Diseases:
The rising prevalence of cardiovascular diseases (CVDs), including coronary artery disease (CAD), heart attacks, and strokes, is stimulating the market growth. Along with this, the growing prevalence of sedentary lifestyles, unhealthy diets, smoking, and increasing stress levels that contribute to the growing incidence of these conditions is fostering the market growth. In line with this, the increasing need for effective and reliable treatment options, such as drug-eluting stents that have proven to be highly effective in reducing the recurrence of arterial blockages post-angioplasty, is enhancing the market growth.
- Imposition of Favorable Reimbursement Policies and Healthcare Expenditure:
The implementation of favorable reimbursement policies and increased healthcare expenditure are critical factors driving the market growth. Along with this, the rising recognition among governments and healthcare payers of the long-term benefits of using DES, leading to more comprehensive and supportive reimbursement frameworks, is facilitating the market growth. In line with this, the heightened focus on covering drug-eluting stents under public and private health insurance plans, thereby reducing the financial burden on patients and encouraging wider adoption, is strengthening the market growth. Additionally, the allocation of substantial healthcare budgets towards the treatment and management of cardiovascular diseases, facilitating the procurement and use of advanced medical devices, is promoting the market growth.
Speak to An Analyst: https://www.imarcgroup.com/request?type=report&id=4815&flag=C
Drug-Eluting Stents Market Report Segmentation:
By Coating:
- Polymer Based Coating
- Polymer Free Coating
Polymer free coating represented the largest segment as it reduces the risk of long-term complications associated with polymer degradation and inflammatory responses.
By Drug:
- Sirolimus
- Paclitaxel
- Zotarolimus
- Everolimus
- Biolimus
- Others
Based on the drug, the market has been divided into sirolimus, paclitaxel, zotarolimus, everolimus, biolimus, and others.
By Stent Platform:
- Stainless-steel
- Cobalt-Chromium
- Platinum-Chromium
- Nitinol
- Others
Cobalt-chromium represented the largest segment due to its superior strength, flexibility, and biocompatibility, which enhance stent performance and patient outcomes.
By Generation:
- 1st Generation
- 2nd Generation
- 3rd Generation
- 4th Generation
On the basis of generation, the market has been divided into 1st generation, 2nd generation, 3rd generation, and 4th generation.
By Application:
- Coronary Artery Disease
- Peripheral Artery Disease
Coronary artery disease accounted for the largest market share as it remains the most prevalent cardiovascular condition requiring stent interventions to restore blood flow and prevent heart attacks.
By End User:
- Hospitals
- Ambulatory Surgical Centers
- Others
Hospitals accounted for the largest market share as they perform the majority of percutaneous coronary interventions and have the necessary infrastructure for advanced cardiac care.
Regional Insights:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
North America's dominance in the drug-eluting stents market is attributed to its advanced healthcare system, high prevalence of cardiovascular diseases, and significant investment in medical research and technology.
Global Drug-Eluting Stents Market Trends:
The increasing focus on personalized medicine, which is leading to the development of customized stents tailored to individual patient needs, is anticipated to drive the market growth. Besides this, the widespread expansion of DES applications in peripheral artery disease, neurovascular conditions, and non-vascular applications, such as the treatment of urethral and biliary strictures, is creating a positive outlook for the market growth. Additionally, the rising adoption of minimally invasive (MI) techniques and robotic-assisted interventions that improve the precision and success rates of stent placements is driving the market growth.
Top Companies Operated in Drug-Eluting Stents Industry:
- Abbott Laboratories
- B. Braun Melsungen AG
- Biosensors International Group Ltd.
- Biotronik
- Boston Scientific Corporation
- Cardinal Health Inc.
- Cook Medical LLC (Cook Group Incorporated)
- Lepu Medical Technology (Beijing) Co. Ltd.
- Medtronic plc
- MicroPort Scientific Corporation
- Sino Medical Sciences Technology Inc.
- Terumo Corporation.
- Key Highlights of the Report:
• Market Performance (2018-2023)
• Market Outlook (2024-2032)
• Market Trends
• Market Drivers and Success Factors
• Impact of COVID-19
• Value Chain Analysis
• Comprehensive mapping of the competitive landscape
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us:
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-631-791-1145
